Literature DB >> 20956816

The impact of surgery, radiation, and systemic treatment on outcomes in patients with ductal carcinoma in situ.

Robert L Kane1, Beth A Virnig, Tatyana Shamliyan, Shi-Yi Wang, Todd M Tuttle, Timothy J Wilt.   

Abstract

BACKGROUND: Ductal carcinoma in situ (DCIS) is associated with low rates of mortality. Outcomes are generally assessed in terms of recurrence.
METHODS: Published studies were abstracted from MEDLINE and other sources. We include articles published through January 31, 2009; 10 publications of five randomized controlled trials and 133 publications of 64 observational studies were reviewed.
RESULTS: Whole-breast radiation therapy following breast-conserving surgery (BCS) was consistently associated with a reduced incidence of local DCIS recurrence and local invasive carcinoma. Women undergoing mastectomy were less likely than women undergoing lumpectomy with or without radiation to experience local DCIS or invasive recurrence. Tamoxifen use reduced risk of recurrent DCIS or invasive carcinoma.
CONCLUSIONS: BCS plus radiation and mastectomy appear to yield equivalent outcomes, whereas BCS alone tends to be inferior to mastectomy. Tamoxifen seems helpful in treating DCIS.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20956816      PMCID: PMC5161061          DOI: 10.1093/jncimonographs/lgq022

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  15 in total

1.  Preliminary results and evaluation of MammoSite balloon brachytherapy for partial breast irradiation for pure ductal carcinoma in situ: a phase II clinical study.

Authors:  Pamela R Benitez; Oscar Streeter; Frank Vicini; Vivek Mehta; Coral Quiet; Robert Kuske; Mary Katherine Hayes; Doug Arthur; Henry Kuerer; Gary Freedman; Martin Keisch; Thomas Dipetrillo; David Khan; Richard Hudes
Journal:  Am J Surg       Date:  2006-10       Impact factor: 2.565

Review 2.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.

Authors:  Nina Bijker; Philip Meijnen; Johannes L Peterse; Jan Bogaerts; Irène Van Hoorebeeck; Jean-Pierre Julien; Massimiliano Gennaro; Philippe Rouanet; Antoine Avril; Ian S Fentiman; Harry Bartelink; Emiel J Th Rutgers
Journal:  J Clin Oncol       Date:  2006-06-26       Impact factor: 44.544

4.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853.

Authors:  N Bijker; J L Peterse; L Duchateau; J P Julien; I S Fentiman; C Duval; S Di Palma; J Simony-Lafontaine; I de Mascarel; M J van de Vijver
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

5.  The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis.

Authors:  Joan L Warren; Donald L Weaver; Therese Bocklage; Charles R Key; Charles E Platz; Kathleen A Cronin; Rachel Ballard-Barbash; Shawna C Willey; Linda C Harlan
Journal:  Cancer       Date:  2005-11-01       Impact factor: 6.860

6.  Initial outcomes for patients treated on the American Society of Breast Surgeons MammoSite clinical trial for ductal carcinoma-in-situ of the breast.

Authors:  Jacqueline S Jeruss; Frank A Vicini; Peter D Beitsch; Bruce G Haffty; Coral A Quiet; Victor J Zannis; Angela J Keleher; Delia M Garcia; Howard C Snider; Mark A Gittleman; Eric Whitacre; Pat W Whitworth; Richard E Fine; Stacey Arrambide; Henry M Kuerer
Journal:  Ann Surg Oncol       Date:  2006-05-16       Impact factor: 5.344

7.  Effectiveness of radiation therapy in older women with ductal carcinoma in situ.

Authors:  Benjamin D Smith; Bruce G Haffty; Thomas A Buchholz; Grace L Smith; Deron H Galusha; Justin E Bekelman; Cary P Gross
Journal:  J Natl Cancer Inst       Date:  2006-09-20       Impact factor: 13.506

8.  Ductal carcinoma in situ: trends in geographic, temporal, and demographic patterns of care and survival.

Authors:  Sue A Joslyn
Journal:  Breast J       Date:  2006 Jan-Feb       Impact factor: 2.431

9.  Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial.

Authors:  Joan Houghton; W D George; Jack Cuzick; Catherine Duggan; Ian S Fentiman; Margaret Spittle
Journal:  Lancet       Date:  2003-07-12       Impact factor: 79.321

10.  Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast.

Authors:  Lars Holmberg; Hans Garmo; Bengt Granstrand; Anita Ringberg; Lars-Gunnar Arnesson; Kerstin Sandelin; Per Karlsson; Harald Anderson; Stefan Emdin
Journal:  J Clin Oncol       Date:  2008-02-04       Impact factor: 44.544

View more
  11 in total

1.  Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: a study based on NSABP protocol B-24.

Authors:  D Craig Allred; Stewart J Anderson; Soonmyung Paik; D Lawrence Wickerham; Iris D Nagtegaal; Sandra M Swain; Elefetherios P Mamounas; Thomas B Julian; Charles E Geyer; Joseph P Costantino; Stephanie R Land; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-03-05       Impact factor: 44.544

2.  Ductal carcinoma in situ (DCIS): posttreatment follow-up care among Latina and non-Latina White women.

Authors:  Mónica E López; Celia P Kaplan; Anna M Nápoles; Jennifer C Livaudais; E Shelley Hwang; Susan L Stewart; Joan Bloom; Leah Karliner
Journal:  J Cancer Surviv       Date:  2013-02-14       Impact factor: 4.442

3.  DEGRO practical guidelines: radiotherapy of breast cancer II: radiotherapy of non-invasive neoplasia of the breast.

Authors:  R Souchon; M-L Sautter-Bihl; F Sedlmayer; W Budach; J Dunst; P Feyer; R Fietkau; W Haase; W Harms; F Wenz; R Sauer
Journal:  Strahlenther Onkol       Date:  2014-01       Impact factor: 3.621

4.  Mammographic features of calcifications in DCIS: correlation with oestrogen receptor and human epidermal growth factor receptor 2 status.

Authors:  Min Sun Bae; Woo Kyung Moon; Jung Min Chang; Nariya Cho; So Yeon Park; Jae-Kyung Won; Yoon-Kyung Jeon; Hyeong-Gon Moon; Wonshik Han; In Ae Park
Journal:  Eur Radiol       Date:  2013-03-20       Impact factor: 5.315

5.  Final results from a multicenter prospective study ( JROSG 05-5) on postoperative radiotherapy for patients with ductal carcinoma in situ with an involved surgical margin or close margin widths of 1 mm or less.

Authors:  Naoto Shikama; Kenji Sekiguchi; Naoki Nakamura; Hiroshi Sekine; Yuko Nakayama; Kazufumi Imanaka; Takeshi Akiba; Masahiko Aoki; Yoshiomi Hatayama; Etsuyo Ogo; Yoshikazu Kagami; Miho Kawashima; Kumiko Karasawa
Journal:  J Radiat Res       Date:  2015-06-20       Impact factor: 2.724

6.  A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast.

Authors:  Lawrence J Solin; Robert Gray; Frederick L Baehner; Steven M Butler; Lorie L Hughes; Carl Yoshizawa; Diana B Cherbavaz; Steven Shak; David L Page; George W Sledge; Nancy E Davidson; James N Ingle; Edith A Perez; William C Wood; Joseph A Sparano; Sunil Badve
Journal:  J Natl Cancer Inst       Date:  2013-05-02       Impact factor: 13.506

7.  Role of the radiotherapy boost on local control in ductal carcinoma in situ.

Authors:  Olivier Riou; Claire Lemanski; Vanessa Guillaumon; Olivier Lauche; Pascal Fenoglietto; Jean-Bernard Dubois; David Azria
Journal:  Int J Surg Oncol       Date:  2012-04-08

8.  COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment.

Authors:  D Generali; F M Buffa; S Deb; M Cummings; L E Reid; M Taylor; D Andreis; G Allevi; G Ferrero; D Byrne; M Martinotti; A Bottini; A L Harris; S R Lakhani; S B Fox
Journal:  Br J Cancer       Date:  2014-05-29       Impact factor: 7.640

9.  Computational pathology to discriminate benign from malignant intraductal proliferations of the breast.

Authors:  Fei Dong; Humayun Irshad; Eun-Yeong Oh; Melinda F Lerwill; Elena F Brachtel; Nicholas C Jones; Nicholas W Knoblauch; Laleh Montaser-Kouhsari; Nicole B Johnson; Luigi K F Rao; Beverly Faulkner-Jones; David C Wilbur; Stuart J Schnitt; Andrew H Beck
Journal:  PLoS One       Date:  2014-12-09       Impact factor: 3.240

10.  Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Authors:  Lotte E Elshof; Michael Schaapveld; Marjanka K Schmidt; Emiel J Rutgers; Flora E van Leeuwen; Jelle Wesseling
Journal:  Breast Cancer Res Treat       Date:  2016-09-08       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.